US 12,441,716 B2
Compositions and methods for increasing muscle mass and oxidative metabolism
Melissa Spencer, Los Angeles, CA (US); Varghese John, Los Angeles, CA (US); Irina Kramerova, Los Angeles, CA (US); Jian Liu, Los Angeles, CA (US); Jesus Campagna, Los Angeles, CA (US); and Barbara Jagodzinska, Los Angeles, CA (US)
Assigned to The Regents of The University of California, Oakland, CA (US)
Appl. No. 17/602,989
Filed by The Regents of the University of California, Oakland, CA (US)
PCT Filed Apr. 9, 2020, PCT No. PCT/US2020/027510
§ 371(c)(1), (2) Date Oct. 11, 2021,
PCT Pub. No. WO2020/210521, PCT Pub. Date Oct. 15, 2020.
Claims priority of provisional application 62/833,037, filed on Apr. 12, 2019.
Prior Publication US 2022/0162198 A1, May 26, 2022
Int. Cl. C07D 405/12 (2006.01); A61K 31/506 (2006.01); A61P 21/00 (2006.01); C07D 405/14 (2006.01); C07D 491/056 (2006.01)
CPC C07D 405/12 (2013.01) [A61K 31/506 (2013.01); A61P 21/00 (2018.01); C07D 405/14 (2013.01); C07D 491/056 (2013.01)] 5 Claims
 
1. A method of treating muscular dystrophy in a subject, the method comprising administering to the subject an effective amount of a compound having a chemical structure of

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt or solvate thereof to treat the muscular dystrophy.